87808-48-8

Basic information

• Product Name: RARECHEM AL BF 0500
• Synonyms: RARECHEM AL BF 0500;METHYL 3-FLUORO-4-METHYLBENZOATE;3-Fluoro-4-methyl-Benzoic acid methyl ester
• CAS NO: 87808-48-8
• Molecular Formula: C₉H₉FO₂
• Molecular Weight: 168.16
• Mol File: 87808-48-8.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 222.1°C at 760 mmHg
• Flash Point: 85.8°C
• Appearance: /
• Density: 1.137g/cm³
• Vapor Pressure: 0.104mmHg at 25°C
• Refractive Index: 1.491
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: RARECHEM AL BF 0500(CAS DataBase Reference)
• NIST Chemistry Reference: RARECHEM AL BF 0500(87808-48-8)
• EPA Substance Registry System: RARECHEM AL BF 0500(87808-48-8)

Safety Data

• Hazardous Substances Data: 87808-48-8(Hazardous Substances Data)

Usage

General Description

RARECHEM AL BF 0500 is a chemical compound with the molecular formula C14H12O3S, belonging to the class of benzofurans. It is a rare and potentially hazardous chemical used primarily in research and development. It has a high purity level and is typically used in pharmaceutical and agrochemical applications. Due to its rare and specialized nature, RARECHEM AL BF 0500 may have limited availability and may require special handling and storage precautions. It is important to carefully follow all safety guidelines and regulations when working with this chemical.

InChI:InChI=1/C9H9FO2/c1-6-3-4-7(5-8(6)10)9(11)12-2/h3-5H,1-2H3

Upstream product

• 99-75-2 4-methyl-benzoic acid methyl ester 
• 350-28-7 3-fluoro-4-methyl-benzoic acid 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 67-56-1 methanol 
• 59189-97-8 3-fluoro-4-methylbenzoic acid chloride 

Downstream Products

• 128577-47-9 methyl 4-(bromomethyl)-3-fluorobenzoate 
• 1134777-51-7 4-dibromomethyl-3-fluorobenzoic acid methyl ester 

Relevant articles and documents

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel

TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, tr

Synthesis of novel 3-substituted benzamides related to imatinib

Twelve new 3-substituted benzamide derivatives structurally related to tyrosine kinase inhibitor imatinib have been synthesised by a Cu(I)-catalysed coupling of three previously synthesised (5-iodo-2-methylphenyl)-[4-(pyridin-3-yl)-6-perfluoroalkylpyrimidin-2-yl]amines with four synthesised 3-substituted 4-(4-methylpiperazin-1-ylmethyl)benzamides.